Truist cuts Boston Scientific stock price target on growth outlook By Investing.com

Boston Scientific reported Q1 2026 revenue of $5.20 billion, ahead of the $5.17 billion consensus, and adjusted EPS of $0.80 versus $0.79 expected, but it cut full-year guidance. Truist lowered its price target to $85 from $90 while keeping a Buy rating, citing better-than-feared Watchman and electrophysiology trends but slower growth ahead. The company also announced a $2 billion share repurchase program, partially offsetting the cautious outlook.

Analysis

The most important read-through is not about near-term demand, but about manufacturing optionality. If a hyperscaler/EV platform like Tesla is willing to publicize an external foundry path on an advanced node, it meaningfully improves Intel’s strategic credibility with other customers who value geopolitical diversification and second-source capacity. The second-order effect is on the ecosystem: equipment, materials, and EDA vendors tied to leading-edge ramps may see a broader “de-risk U.S. capacity” narrative, while incumbent pure-play foundries face a higher bar on allocation transparency and customer lock-in.

For Intel, this is less a fundamentals story for next quarter than a path-reopening event over the next 12-24 months. The market has been pricing the company as a technology laggard with limited foundry relevance; any external validation that advanced process roadmaps are commercially usable can compress that discount faster than operating results alone. The risk is execution slippage — one delayed node milestone or poor yield disclosure would quickly unwind the credibility premium, so the trade is really a series of catalyst windows rather than a set-and-forget long.

BSX is a different setup: the lowered guide and subsequent analyst reset may finally clear a sentiment overhang, but the key second-order issue is decelerating growth in businesses that had been priced for persistence. When a medtech franchise still grows mid/high single digits and buys back stock, the stock can de-rate less than feared if the market was expecting a harder reset; however, that also means upside now depends on visible acceleration, not just “less bad” numbers. The contrarian angle is that consensus may be too focused on the quarter and not enough on 2027-28 operating leverage, but the stock likely needs either another beat/raise or a cleaner evidence point on procedure recovery to re-rate materially.

Key Decisions for Investors

• Buy INTC on weakness over the next 1-3 weeks; treat Musk/Tesla validation as a sentiment catalyst with 3-6 month upside if the market starts underwriting foundry credibility. Risk/reward is attractive for a tactical long, but size modestly because execution risk remains high.
• Pair trade: long INTC / short a mature foundry or equipment proxy on a 1-3 month horizon to express relative re-rating from U.S. advanced-node optionality. Use a tight stop if Intel fails to sustain follow-through after the headline fades.
• Sell cash-secured puts on BSX at strikes 5-10% below spot for 1-2 quarters out to harvest elevated uncertainty premium. The setup favors premium capture if the name stabilizes, while limiting downside if guidance revisions continue.
• For a cleaner BSX expression, wait for one more quarter of procedure data before adding outright long exposure; buy only if management proves acceleration in 2H, otherwise the stock can stay value-trapped for months.